Open Label Phase I Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia (With Pilot Feasibility Study in Combination With Pegylated Interferon Alfa 2a for Patients Who do Not Respond to the Single Agent at Each Dose Level)
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 18 Jun 2018
At a glance
- Drugs Idasanutlin (Primary) ; Peginterferon alfa-2a
- Indications Essential thrombocythaemia; Polycythaemia vera
- Focus Adverse reactions
- 08 Jun 2018 Planned End Date changed from 1 Apr 2018 to 1 Dec 2019.
- 08 Jun 2018 Planned primary completion date changed from 1 Apr 2017 to 1 Dec 2019.
- 08 Jun 2018 Status changed from recruiting to active, no longer recruiting.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History